| ASYMCHEM-LIFE-SCIENCE-CO-LTD |
ASYMCHEM-LIFE-SCIENCE-CO-LTD |
85%
|
e API is derived is kept at a storage facility maintained by Charles River Laboratories Inc. Adrulipase drug substance and drug product are currently manufactured at a contract facility located in Ti… |
| GOVERNMENT-REGULATION-GRID-AI-CORP |
GOVERNMENT-REGULATION-GRID-AI-CORP |
85%
|
r plants, and wholesale market participation. Changes in laws, regulations, market rules, or regulatory interpretations could impact the ability of customers to deploy Grid AI Corp.’ solutions, parti… |
| GRIS-AI-CORP |
GRIS-AI-CORP |
85%
|
gh direct sales and strategic partnerships with energy developers, system integrators, engineering firms, and other industry participants. Gris Ai Corp. has commenced early-stage development activiti… |
| MAJOR-CUSTOMERS-GRID-AI-CORP |
MAJOR-CUSTOMERS-GRID-AI-CORP |
85%
|
ill depend on the progress of customer projects, including construction and operational readiness milestones, as well as the availability of customer funding. -3- Table of Contents Sources and Availa… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from GRDX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from GRDX graph: parties as set forth in the Resci… |
| SNYNF |
Sanofi |
72%
|
parties as set forth in the Rescission Agreement to consummate the transactions contemplated by this Agreement, (ii) the Shareholders shall have delivered a mutually satisfactory voting agreement agr… |
| ACCORDINGLY-GRID-AI-CORP |
ACCORDINGLY-GRID-AI-CORP |
62%
|
hin financial statements), is a current customer with whom Grid AI Corp. has been engaged in ongoing collaboration since October 1, 2025; however, as of the date of this report, the parties remain un… |
| AGREEMENTS-GRID-AI-CORP |
AGREEMENTS-GRID-AI-CORP |
62%
|
hin financial statements), is a current customer with whom Grid AI Corp. has been engaged in ongoing collaboration since October 1, 2025; however, as of the date of this report, the parties remain un… |
| AI-CORP |
AI-CORP |
62%
|
id AI Corp. is developing and will seek to develop in the future does not grow as anticipated, or if competitors offer more attractive products, our and Grid AI Corp.’s revenue growth and market posi… |
| AI-DATA-CENTER-DEVELOPED-TECHNOLOGY-FOLLOWING-GR |
AI-DATA-CENTER-DEVELOPED-TECHNOLOGY-FOLLOWING-GR |
62%
|
platform, many were unwilling to replace existing deployed systems that were viewed as sufficiently effective. The Company, together with Grid AI Corp., is currently re-evaluating these opportunities… |
| AI-GRID-AI-CORP |
AI-GRID-AI-CORP |
62%
|
ionality, which could negatively affect customer satisfaction and adoption. In addition, continuing to execute on the new strategy requires investment in new capabilities and resources, particularly … |
| AMPX-GRID-AI-CORP |
AMPX-GRID-AI-CORP |
62%
|
management continues to monitor the commercial viability of these platforms and incorporate such assessments into its broader strategic planning and impairment analyses. Strategic Pivot and Operation… |
| AMPX-UK-HOLDINGS |
AMPX-UK-HOLDINGS |
62%
|
the war in Ukraine and conflicts in the Middle East, on our operations, access to capital, supply chain, third-party relationships and broader market conditions ● the availability of capital to satis… |
| CHARLES-RIVER-LABORATORIES-INC |
CHARLES-RIVER-LABORATORIES-INC |
62%
|
e API is derived is kept at a storage facility maintained by Charles River Laboratories Inc. Adrulipase drug substance and drug product are currently manufactured at a contract facility located in Ti… |
| CRL |
Charles River Laboratories International, Inc. |
62%
|
Reciprocal relationship from CRL graph: Reciprocal relationship from GRDX graph: e API is derived is kept at a storage facility maintained by Charles River Laboratories Inc. Adrulipase drug substance… |
| ENVIRONMENTAL-COMPLIANCE-GRID-AI-CORP |
ENVIRONMENTAL-COMPLIANCE-GRID-AI-CORP |
62%
|
r plants, and wholesale market participation. Changes in laws, regulations, market rules, or regulatory interpretations could impact the ability of customers to deploy Grid AI Corp.’ solutions, parti… |
| FIRST-WAVE-BIO-INC |
FIRST-WAVE-BIO-INC |
62%
|
in the valuation models, including anticipated future cash flows, discount rates, market multiples, risk-free rate, and other inputs, as applicable. To this effect, we utilized our valuation expert t… |
| FOLLOWING-GRID-AI-CORP |
FOLLOWING-GRID-AI-CORP |
62%
|
in jurisdictions such as the U.S. and European Union, could entail significant costs, negatively affect our and Grid AI Corp. business, or limit our and Grid AI Corp.’s ability to incorporate certain… |
| FURTHER-GRID-AI-CORP |
FURTHER-GRID-AI-CORP |
62%
|
data centers. While Grid AI Corp. is looking to develop a data center platform, they have a limited history operating our business at its current scale and under our current strategy, and therefore a… |
| FURTHERMORE-GRID-AI-CORP |
FURTHERMORE-GRID-AI-CORP |
62%
|
in jurisdictions such as the U.S. and European Union, could entail significant costs, negatively affect our and Grid AI Corp. business, or limit our and Grid AI Corp.’s ability to incorporate certain… |
| GOVERNMENT-APPROVALS-GRID-AI-CORP |
GOVERNMENT-APPROVALS-GRID-AI-CORP |
62%
|
ets, trademarks, and contractual protections. Grid AI Corp. does not currently rely on material labor agreements. Government Approvals Grid AI Corp.’s software platform itself generally does not requ… |
| GRID-AI-CORP |
GRID-AI-CORP |
62%
|
stacking of multiple tariff authorities on such products, it could adversely affect Grid AI Corp.’s our business, financial condition and results of operations. Tariffs, and the possibility of additi… |
| HEMS-WHILE-GRID-AI-CORP |
HEMS-WHILE-GRID-AI-CORP |
62%
|
ur management, internal controls and investor disclosures may be subject to heightened execution risk. Grid AI Corp.’s limited operating history makes evaluating its business and prospects difficult.… |
| IF-GRID-AI-CORP |
IF-GRID-AI-CORP |
62%
|
ionality, which could negatively affect customer satisfaction and adoption. In addition, continuing to execute on the new strategy requires investment in new capabilities and resources, particularly … |
| IMMUNOGENX-LLC |
IMMUNOGENX-LLC |
62%
|
r plants, and wholesale market participation. Changes in laws, regulations, market rules, or regulatory interpretations could impact the ability of customers to deploy Grid AI Corp.’ solutions, parti… |
| WHILE-GRID-AI-CORP |
WHILE-GRID-AI-CORP |
62%
|
data centers. While Grid AI Corp. is looking to develop a data center platform, they have a limited history operating our business at its current scale and under our current strategy, and therefore a… |
